Thread by @BigBiteNow

1/6
I would think as #TILS move through the process to demerge Accustem Sciences, the SP should start to trend higher.

Today's RNS confirms the easy bit with the court hearings being the true barrier, be it I see little problem in getting through them.

2/6
I don't buy a £280m IPO valuation because they won't have a test ready for market. Whilst the CE Mark process is 'planned' to begin in November 2020, it won't be completed until well after the IPO.

However, I am certainly enthused by Executive Chairman Gabriele Cerrone's

3/6
"beneficial interest" in the c. 33% of TILS, that is owned by Planwise Group LTD.

What that says is that the push will certainly be on, to maximise the IPO and minimise the dilution required.

I talk about dilution because it will inevitably come with the IPO,

4/6
because c. £1m isn't going to get their product to market.

That said it holds no fear for me, for reasons stated above and the fact that it won't require a huge sum, to get this test to market in 2021.

Therefore, the raise could in fact end up acting as the catalyst,

5/6
for the IPO valuation itself and the subsequent market reaction immediately afterwards.

So on balance, it is for me better to be a shareholder who owns shares prior to the first days trading, as opposed to seeking them later in the market.

6/6
When i start to factor in such things as the Brazil Covid treatment trial, which could act as parallel driver front end, plus the PR driven mentality of the BOD, that view point only strengthens.

So the reward of holding now, certainly out shines the risk for me.

1A
As the temporary reaction in the SP just demonstrated.

Its going to take something a bit more tangible to drive #TILS north but it is for me coming.